AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

11.74 -0.94 (-7.37%)

Delayed Quote Updated: 2:11 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

October 08, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

October 01, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

September 16, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

September 02, 2026

From AbCellera Biologics Inc.

Via Business Wire

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

News Provided by USA News Group on behalf of MindWalk Holdings Corp.

From USA News Group

Via GlobeNewswire

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

August 13, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

AI Found an Influenza Target That Survives Viral Mutation

August 10, 2026

Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)

From Equity Insider

Via GlobeNewswire

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

August 10, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

August 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Reports Q2 2026 Business Results

August 05, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

July 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

July 06, 2026

From AbCellera Biologics Inc.

Via Business Wire

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

June 17, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

June 05, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

April 20, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

April 01, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Reports Full Year 2025 Business Results

February 24, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

February 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

January 22, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

January 12, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera and Bruker Reach Global Settlement of Patent Litigation

December 18, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

November 10, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Reports Q3 2025 Business Results

November 06, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

October 07, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

September 29, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

September 10, 2025

From AbCellera Biologics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >